IVA
Inventiva Sets Sights on Lanifibranor Approval with Disciplined Clinical and Biostatistical Milestones
In a recent conference call to discuss its full year 2025 financial results and business update, Inventiva's CEO Andrew Obenshain outlined the company's strategy for advancing lanifibranor towards approval for patients with Metabolic Associated Steatohepatitis (MASH). According to Obenshain, since joining the company six months ago,